CF(1)iPS5
MHHi002-A
General#
Cell Line |
|
| hPSCreg Name | MHHi002-A |
| Alternative name(s) |
CF(1)iPS5
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | Hannover Medical School (MHH) |
External Databases |
|
| BioSamples | SAMEA103885560 |
| Cellosaurus | CVCL_QX52 |
| CLO | CLO_0101610 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
No |
| Subclones | |
Donor Information#
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA7418668 |
Ethics#
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Provide contact information of the holder of the original Donor Information Sheet: | |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Contact information / weblink | |
| Alternatives to consent | |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Details on restriction to research project | |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does consent permit access to medical records of the donor? | No |
| Please describe how access is provided: | |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Contact data, institution, or website: | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | MHH Ethikkommission |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | MHH Ethikkommission |
| Approval number | |
| Please describe: | |
| Further constraints on use | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution |
hIPSC Derivation#
General |
|
| Source cell type |
endothelial cell内皮细胞包括解剖结构的最外层或衬里，并且可以是鳞状或立方状的。在哺乳动物中，内皮细胞具有波形蛋白丝并且来源于中胚层。; An endothelial cell comprises the outermost layer or lining of anatomical structures and can be squamous or cuboidal. In mammals, endothelial cell has vimentin filaments and is derived from the mesoderm.
Synonyms
|
| Source cell type (free text) | endothelia colony forming cell from peripheral blood |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Lentivirus) |
| Is the used vector excisable? |
Yes |
| Absence of reprogramming vector(s)? |
No |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions#
| Medium |
Other medium:
Base medium: Knockout DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
|||
| SOX2 |
Yes |
|
||||
| NANOG |
Yes |
|
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46[XY]
Passage number: 22
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.